Kinaxis has announced that Swedish Orphan Biovitrum AB (Sobi), a leading international biopharmaceutical company, has elected to implement the Kinaxis Maestro platform to facilitate end-to-end collaboration across its partner network, enable data-driven decisions and support the delivery of critical rare-disease therapies to patients.
With a mission to serve 95% of rare diseases that still lack approved treatments, Sobi operates in a complex and urgent field of healthcare. Headquartered in Stockholm, Sweden, Sobi specialises in hematology, immunology and specialty care, delivering innovative treatments to over 40,000 patients annually across 55 countries. Sobi’s operations have a direct impact on the quality of life of patients suffering from rare conditions – requiring a high degree of speed, precision and visibility across its supply chain.
Maestro’s advanced capabilities in scenario planning, centralised data management and attribute-based planning will support Sobi to strengthen partner connectivity, scale operations, and respond faster to potential disruptions to facilitate the supply of critical therapies for rare diseases to patients with high medical needs.
“Kinaxis is well-regarded in the life sciences sector for its understanding of the unique complexities of supply chains that define this specific industry,” said Norbert Schoellhorn, vice president of global manufacturing and supply chain at Sobi. “We believe that Kinaxis will help us connect better with our partners, respond faster to change and deliver life-changing treatments to patients who can’t afford to wait.”
“Sobi’s work changes lives, and we’re proud to support them in delivering on that mission,” said Fabienne Cetre, executive vice president of EMEA at Kinaxis. “Sobi will utilise Maestro to unlock real-time collaboration and seamless execution in order to fast-track the delivery of critical therapies worldwide.”
